Trial
NCT00576056
Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Pittsburgh
Collaborators
Bayer
Condition
Carcinoma, Hepatocellular
Intervention
Sorafenib
Why stopped
Bayer Healthcare is no supplying the study drug
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-15